Overview

Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. We are developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis and rosnilimab, our PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Our preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases.

In addition, Anaptys has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, that has completed Phase 3 trials for the treatment of generalized pustular psoriasis, and etokimab, an anti-IL-33 antagonist that is Phase 2/3 ready. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist antibody (JemperliTM (dostarlimab-gxly)) and an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889).

Strategy

Enable broad development of our best-in-class immune cell modulators in AD, RA, and UC, respectively.

Generate in vitro and in vivo translational and clinical data to inform the potential differentiation of our molecules from in-class competitors and standard of care, and identify patient populations most likely to have deeper and/or more durable responses by restoring immune balance.

Facilitate the global commercialization of our checkpoint agonists while retaining rights in key therapeutic areas and/or commercial markets to enable us to become a fully integrated discovery, development and commercial organization.

Continue to leverage our research platform to generate potentially best-in-class antibodies against high-value immunological targets.

Senior Leadership

Angela Stambaugh

Angela Stambaugh

Vice President, Program Management
Ben Stone

Ben Stone

Chief Business Officer
Beth Mueller

Beth Mueller

Senior Vice President, Human Resources
Daniel Faga

Daniel Faga

President & CEO
Dennis Mulroy

Dennis Mulroy

Chief Financial Officer
Doug Rich, M.B.A.

Doug Rich, M.B.A.

Senior Vice President, CMC
Ellen Zigmont, Pharm.D., BCOP

Ellen Zigmont, Pharm.D., BCOP

Vice President, Medical Affairs
Eric Loumeau, J.D.

Eric Loumeau, J.D.

Chief Legal Officer
Kenneth Luu, Ph.D.

Kenneth Luu, Ph.D.

Vice President, Clinical Pharmacology
Lewis Gryziewicz, Pharm.D.

Lewis Gryziewicz, Pharm.D.

Vice President, Regulatory Affairs
Martin Dahl, Ph.D.

Martin Dahl, Ph.D.

Senior Vice President, Research
Monique da Silva

Monique da Silva

Senior Vice President, Corporate Affairs
Pejman Soroosh, Ph.D.

Pejman Soroosh, Ph.D.

Vice President, Immunology
Priya Raina

Priya Raina

Senior Vice President, Clinical Operations
Stephen Parmley, Ph.D.

Stephen Parmley, Ph.D.

Vice President, Protein Sciences

Spotlight on Medical & Clinical Development Expertise

Bruce Randazzo, M.D., Ph.D., FAAD

Bruce Randazzo, M.D., Ph.D., FAAD

Vice President, Clinical Development
Cailin Sibley, M.D., MHS, FACR

Cailin Sibley, M.D., MHS, FACR

Vice President, Translational Medicine

Board Of Directors

Daniel Faga

President & CEO

Dan has more than 20 years of operating and advisory experience in the life sciences industry. He has served as Anaptys’ president and chief executive officer since March 2022. Previously, he was chief operating officer at Mirati Therapeutics responsible for leading the company’s corporate strategy, finance, legal and other business operations.

+

Dennis Fenton, Ph.D.

Former Executive Vice President, Amgen

Dr. Fenton held positions of increasing responsibility at Amgen from 1982 through to his retirement in 2008, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President.

+

Rita Jain, M.D.

Former Executive Vice President and Chief Medical Officer of ChemoCentryx

Rita Jain, M.D., joined our Board of Directors in April 2023. Dr. Jain is a rheumatologist and currently serves on the Board of Directors of Provention Bio, Inc. and Celldex Therapeutics, and serves on the supervisory board of AM Pharma.

+

Magda Marquet, Ph.D.

Co-founder of Althea Technologies, AltheaDx and ALMA Life Sciences, LLC

Dr. Magda Marquet joined our Board of Directors in January 2021. She was the co-CEO of Althea Technologies from 2000 to 2008. She is currently the co-CEO of Alma Life Sciences. LLC, an investment and consulting firm and serves on several Boards of Directors.

+

Oleg Nodelman

Founder and Portfolio Manager of EcoR1 Capital LLC

Oleg Nodelman joined our Board of Directors in April 2021. He is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, and has nearly twenty years of experience in biotech investing.

+

John Orwin

Board Chairman of Anaptys
CEO of Atreca

John Orwin serves on the Board of Directors of Seagen, Inc., Travere Therapeutics and Cargo Therapeutics. He previously served on the Board of Directors of Array BioPharma, Inc. He also currently serves as president and CEO of Atreca, Inc., a clinical-stage biotechnology company, and previously was the CEO of Relypsa, until its acquisition by Galenica, and CEO of Affymax.

+

Hollings Renton

Former President and CEO of Onyx Pharmaceuticals

Hollings Renton has previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals from 1993 to 2008 and as the Chairman of the Board from 2000 to 2008.

+

John Schmid

Former CFO of Auspex Pharmaceuticals

John Schmid has over 35 years of experience in financial and senior management in the biotech industry and has raised over $900 million in private and public equity as well debt financings as a Chief Financial Officer.

+

J. Anthony Ware, M.D.

Former SVP Product Development, Lilly Bio-Medicines, Eli Lilly and Company

Dr. Ware served as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he was responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas.

+

Scientific Advisory Board

Christopher Hunter, Ph.D.

Mindy Halikman Heyer President’s Distinguished Chair and former chair of the Department of Pathobiology at the University of Pennsylvania School of Veterinary Medicine

Christopher Hunter, Ph.D., is the Mindy Halikman Heyer President’s Distinguished Chair and former chair of the Department of Pathobiology at the University of Pennsylvania School of Veterinary Medicine. Dr. Hunter’s research has focused on the host’s immune response to infections and the innate events that lead to the development of long term protective immunity mediated […]

+

John G. Monroe, Ph.D.

Emeritus Professor, University of Pennsylvania School of Medicine

John G. Monroe, Ph.D., is an Emeritus Professor at the Perelman School of Medicine at the University of Pennsylvania. He is a former Senior Director at Genentech where he led the Immunology Discovery Department that is responsible for new target discovery and pre-clinical validation.

+

Luisa Salter-Cid, PH.D.

Chief Scientific Officer, Pioneering Medicines

Luisa Salter-Cid, Ph.D., is currently Chief Scientific Officer at Pioneering Medicines. Throughout her career Dr. Salter-Cid has authored of over 90 publications and patents.

+

Dolca Thomas, M.D.

Venture Partner, Board Member Allakos Therapeutics, Ventus Therapeutics

Dolca Thomas, M.D., is currently a venture partner at Samsara BioCapital and serves on the Board of Directors of Allakos Therapeutics and Ventus Therapeutics. Dr. Thomas has extensive experience in both large pharma and biotech.

+

Contact

AnaptysBio, Inc.

10770 Wateridge Circle
Suite 210
San Diego, CA 92121-5801

 

Phone: (858) 362-6295
info@anaptysbio.com

General Information

info@anaptysbio.com

Investor Inquiries

investors@anaptysbio.com

Media Inquiries

media@anaptysbio.com

Job Opportunities

Please see our Job Openings page.

Sponsorships

sponsorships@anaptysbio.com